CN1913917B - 凝血酶肽衍生物的药物组合物 - Google Patents

凝血酶肽衍生物的药物组合物 Download PDF

Info

Publication number
CN1913917B
CN1913917B CN2004800414872A CN200480041487A CN1913917B CN 1913917 B CN1913917 B CN 1913917B CN 2004800414872 A CN2004800414872 A CN 2004800414872A CN 200480041487 A CN200480041487 A CN 200480041487A CN 1913917 B CN1913917 B CN 1913917B
Authority
CN
China
Prior art keywords
gly
pharmaceutical composition
asp
pro
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800414872A
Other languages
English (en)
Chinese (zh)
Other versions
CN1913917A (zh
Inventor
D·W·霍布森
R·S·克劳瑟
D·H·卡尼
A·P·K·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capstone Therapy Co
University of Texas System
Original Assignee
Orthologic Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthologic Corp filed Critical Orthologic Corp
Publication of CN1913917A publication Critical patent/CN1913917A/zh
Application granted granted Critical
Publication of CN1913917B publication Critical patent/CN1913917B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN2004800414872A 2003-12-31 2004-12-30 凝血酶肽衍生物的药物组合物 Expired - Fee Related CN1913917B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53373003P 2003-12-31 2003-12-31
US60/533,730 2003-12-31
PCT/US2004/044012 WO2005065706A1 (en) 2003-12-31 2004-12-30 Pharmaceutical composition for thrombin peptide derivatives

Publications (2)

Publication Number Publication Date
CN1913917A CN1913917A (zh) 2007-02-14
CN1913917B true CN1913917B (zh) 2012-02-01

Family

ID=34652502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800414872A Expired - Fee Related CN1913917B (zh) 2003-12-31 2004-12-30 凝血酶肽衍生物的药物组合物

Country Status (13)

Country Link
US (2) US7291596B2 (enExample)
EP (1) EP1559431B1 (enExample)
JP (1) JP5044829B2 (enExample)
CN (1) CN1913917B (enExample)
AT (1) ATE357928T1 (enExample)
AU (1) AU2004312090B2 (enExample)
CA (1) CA2551525C (enExample)
DE (1) DE602004005564T2 (enExample)
DK (1) DK1559431T3 (enExample)
ES (1) ES2287660T3 (enExample)
PL (1) PL1559431T3 (enExample)
PT (1) PT1559431E (enExample)
WO (1) WO2005065706A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4668612B2 (ja) * 2002-07-02 2011-04-13 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体ダイマー
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
CA2663547C (en) * 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
WO2009120304A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
US20110105400A1 (en) * 2008-03-26 2011-05-05 Orthologic Corp. Methods for treating acute myocardial infarction
WO2009120300A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating degenerative diseases
AU2009229402A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2011106222A2 (en) 2010-02-23 2011-09-01 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
CA2922748C (en) * 2013-10-03 2021-05-25 Luis Alberto AMESTICA SALAZAR Biocidal resin composition including one or a plurality of resins selected from mf, uf, pf, muf and phenolic resins; and more than one soluble copper salt
ES2755941T3 (es) 2014-05-15 2020-04-24 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CN105879010A (zh) * 2015-01-17 2016-08-24 内蒙古天奇生物科技有限公司 一种能促进创伤愈合减轻创后瘢痕的多肽组合物及其制备方法
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CA3135790A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions
JP2023139750A (ja) * 2022-03-22 2023-10-04 株式会社東芝 抗酸化剤を用いたｆｅｔセンサ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409334A (en) * 1980-05-22 1983-10-11 Boehringer Mannheim Gmbh Stabilized thrombin preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
JP2000229882A (ja) * 1998-12-10 2000-08-22 Sankyo Co Ltd 修飾シクロデキストリン含有トロンビン水性液剤
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
TR200400260T4 (tr) 2000-07-19 2004-03-22 The Board Of Regents, The University Of Texas System Trombin peptid türevleri ile kemik büyümesinin uyarılması
EP1259598B1 (en) * 2000-07-20 2004-09-22 The Board of Regents, The University of Texas System Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
HUP0301892A3 (en) * 2000-11-17 2005-06-28 Warner Lambert Company Llc Mor Pharmaceutical compositions for treatment of sexual dysfunction and their preparation
WO2002074806A2 (en) * 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
AU2002236768B2 (en) 2001-07-27 2006-06-08 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
CN100372567C (zh) 2002-01-16 2008-03-05 奥索洛吉艾斯有限公司 促进心脏组织修复的凝血酶衍生肽
JP2005519067A (ja) 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
ES2377959T3 (es) * 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
CA2491052A1 (en) * 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
JP4668612B2 (ja) 2002-07-02 2011-04-13 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体ダイマー

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409334A (en) * 1980-05-22 1983-10-11 Boehringer Mannheim Gmbh Stabilized thrombin preparation

Also Published As

Publication number Publication date
ES2287660T3 (es) 2007-12-16
DK1559431T3 (da) 2007-07-30
PL1559431T3 (pl) 2007-10-31
US7291596B2 (en) 2007-11-06
US7875588B2 (en) 2011-01-25
AU2004312090A1 (en) 2005-07-21
US20090054343A1 (en) 2009-02-26
AU2004312090B2 (en) 2008-08-14
WO2005065706A1 (en) 2005-07-21
EP1559431B1 (en) 2007-03-28
CA2551525C (en) 2013-02-19
HK1080390A1 (en) 2006-04-28
CA2551525A1 (en) 2005-07-21
DE602004005564D1 (de) 2007-05-10
DE602004005564T2 (de) 2007-12-13
JP5044829B2 (ja) 2012-10-10
US20050203017A1 (en) 2005-09-15
JP2007518724A (ja) 2007-07-12
ATE357928T1 (de) 2007-04-15
CN1913917A (zh) 2007-02-14
PT1559431E (pt) 2007-07-02
EP1559431A1 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
CN1913917B (zh) 凝血酶肽衍生物的药物组合物
US7919457B2 (en) Thrombin peptide derivative dimers
US6894027B2 (en) Stimulation of bone growth with thrombin peptide derivatives
JP2005053930A (ja) 非タンパク質分解的活性化トロンビンレセプターのアゴニストによる軟骨成長の刺激
US7713934B2 (en) Thrombin peptide derivatives
AU2002239965B2 (en) Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
HK1080390B (en) Pharmaceutical composition for thrombin peptide derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER OWNER: CAPSTONE THERAPEUTICS CORP.

Effective date: 20130826

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: CAPSTONE THERAPEUTICS CORP.

Free format text: FORMER NAME: UNIV TEXAS

CP01 Change in the name or title of a patent holder

Address after: Arizona USA

Patentee after: Capstone therapy Co.

Address before: Arizona USA

Patentee before: ORTHOLOGIC Corp.

TR01 Transfer of patent right

Effective date of registration: 20130826

Address after: Texas in the United States

Patentee after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Address before: Arizona USA

Patentee before: Capstone therapy Co.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120201

Termination date: 20131230